COLL Stock Analysis: Collegium Pharmaceutical | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 771m USD | 12M Return: -29.8% | US19459J1043 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.7M
EPS Trend: 85.1%
Qual. Beats: 0
Rev. Trend: 98.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) is a U.S.-based specialty pharmaceutical company that develops and commercializes prescription medicines for pain management. Founded in 2002 and headquartered in Stoughton, Massachusetts, the company markets a portfolio of branded products spanning central nervous system and pain therapies, including Jornay PM (methylphenidate HCl for ADHD), Belbuca (a buprenorphine buccal film for severe persistent pain), Xtampza ER (an abuse-deterrent extended-release oxycodone), Nucynta ER and Nucynta IR (tapentadol formulations), and Symproic (naldemedine for opioid-induced constipation). The company adopted its current name in October 2003 and listed on NASDAQ in May 2015.
Collegium operates within the specialty pharmaceutical segment of the health care industry, focusing on differentiated, branded therapies in targeted therapeutic areas such as pain and central nervous system disorders rather than primary-care mass-market drugs. Several of its products are controlled substances regulated by the DEA, and the company has emphasized abuse-deterrent formulations, a category that has gained regulatory and public health importance in the context of the U.S. opioid epidemic. With a market capitalization of roughly $698 million, COLL is classified as a small-cap health care stock.
- Xtampza ER faces generic erosion as patent protection expires
- Belbuca revenue scales post BioDelivery acquisition
- Opioid prescribing restrictions and DEA quotas pressure pain franchise margins
| Net Income: 47.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 2.70 > 1.0 |
| NWC/Revenue: 2.25% < 20% (prev 11.97%; Δ -9.72% < -1%) |
| CFO/TA 0.15 > 3% & CFO 329.9m > Net Income 47.9m |
| Net Debt (968.6m) to EBITDA (473.4m): 2.05 < 3 |
| Current Ratio: 1.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.5m) vs 12m ago -16.93% < -2% |
| Gross Margin: 60.02% > 18% (prev 56.69%; Δ 3.33% > 0.5%) |
| Asset Turnover: 43.35% > 50% (prev 44.39%; Δ -1.04% > 0%) |
| Interest Coverage Ratio: 1.48 > 6 (EBIT TTM 239.6m / Interest Expense TTM 161.9m) |
| A: 0.01 (Total Current Assets 608.0m - Total Current Liabilities 589.9m) / Total Assets 2.14b |
| B: -0.05 (Retained Earnings -101.7m / Total Assets 2.14b) |
| C: 0.13 (EBIT TTM 239.6m / Avg Total Assets 1.86b) |
| D: 0.17 (Book Value of Equity 311.9m / Total Liabilities 1.82b) |
| Altman-Z'' = 0.94 = BB |
| DSRI: 1.17 (Receivables 285.1m/213.0m, Revenue 808.2m/707.0m) |
| GMI: 0.94 (GM 56.69% / 60.02%) |
| AQI: 1.10 (AQ_t 0.71 / AQ_t-1 0.64) |
| SGI: 1.14 (Revenue 808.2m / 707.0m) |
| TATA: -0.13 (NI 47.9m - CFO 329.9m) / TA 2.14b) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of November 06, 2026, the stock is trading at USD 25.16 with a total of 1,572,971 shares traded. Over the past week, the price has changed by +4.70%, over one month by +15.04%, over three months by -29.60% and over the past year by -29.82%.
Current recommended Stop Loss: 23.10 (which is 8.2% or 2.5 ATR below the current price).
Collegium Pharmaceutical has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy COLL.
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 49 | 94.8% |
P/E Trailing = 18.6378
P/E Forward = 3.51
P/S = 0.9535
P/B = 2.4768
P/EG = 0.7021
Revenue TTM = 808.2m USD
EBIT TTM = 239.6m USD
EBITDA TTM = 473.4m USD
Long Term Debt = 1.04b USD (from longTermDebt, last quarter)
Short Term Debt = 56.6m USD (from shortTermDebt, last quarter)
Debt = 1.10b USD (corrected: LT Debt 1.04b + ST Debt 56.6m) + Leases 4.97m
Net Debt = 968.6m USD (calculated: Debt 1.10b - CCE 129.5m)
Enterprise Value = 1.74b USD (770.6m + Debt 1.10b - CCE 129.5m)
Interest Coverage Ratio = 1.48 (Ebit TTM 239.6m / Interest Expense TTM 161.9m)
EV/FCF = 5.30x (Enterprise Value 1.74b / FCF TTM 328.3m)
FCF Yield = 18.88% (FCF TTM 328.3m / Enterprise Value 1.74b)
FCF Margin = 40.62% (FCF TTM 328.3m / Revenue TTM 808.2m)
Net Margin = 5.93% (Net Income TTM 47.9m / Revenue TTM 808.2m)
Gross Margin = 60.02% ((Revenue TTM 808.2m - Cost of Revenue TTM 323.1m) / Revenue TTM)
Gross Margin QoQ = 55.18% (prev 60.59%)
Tobins Q-Ratio = 0.81 (Enterprise Value 1.74b / Total Assets 2.14b)
Interest Expense / Debt = 14.75% (Interest Expense 161.9m / Debt 1.10b)
Taxrate = 38.32% (29.8m / 77.7m)
NOPAT = 147.8m (EBIT 239.6m * (1 - 38.32%))
Current Ratio = 1.03 (Total Current Assets 608.0m / Total Current Liabilities 589.9m)
Debt / Equity = 3.52 (Debt 1.10b / totalStockholderEquity, last quarter 311.9m)
Debt / EBITDA = 2.05 (Net Debt 968.6m / EBITDA 473.4m)
Debt / FCF = 2.95 (Net Debt 968.6m / FCF TTM 328.3m)
Total Stockholder Equity = 300.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.57% (Net Income 47.9m / Total Assets 2.14b)
RoE = 15.96% (Net Income TTM 47.9m / Total Stockholder Equity 300.2m)
RoCE = 17.93% (EBIT 239.6m / Capital Employed (Equity 300.2m + L.T.Debt 1.04b))
RoIC = 9.46% (NOPAT 147.8m / Invested Capital 1.56b)
WACC = 8.16% (E(770.6m)/V(1.87b) * Re(6.83%) + D(1.10b)/V(1.87b) * Rd(14.75%) * (1-Tc(0.38)))
Discount Rate = 6.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -46.78 | Cagr: -10.28%
[DCF] Terminal Value 77.97% ; FCFF base≈277.7m ; Y1≈318.3m ; Y5≈468.5m
[DCF] Fair Price = 186.8 (EV 7.05b - Net Debt 968.6m = Equity 6.08b / Shares 32.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 85.11 | EPS CAGR: 19.30% | SUE: 0.53 | # QB: 0
Revenue Correlation: 98.35 | Revenue CAGR: 17.46% | SUE: -0.16 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.86 | Chg30d=+1.90% | Revisions=-17% | Analysts=7
EPS current Year (2026-12-31): EPS=7.46 | Chg30d=+1.19% | Revisions=-29% | GrowthEPS=+0.5% | GrowthRev=+6.7%
EPS next Year (2027-12-31): EPS=7.26 | Chg30d=+9.71% | Revisions=+0% | GrowthEPS=-2.7% | GrowthRev=+1.4%
[Analyst] Revisions Ratio: -21% (up=4, down=7)